Skip to main content

Table 1 Demographic characteristics of subjects

From: Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease

  Control (n = 73) RA (n = 43) IBD (n = 42)
Age, y 51 ± 10 55 ± 11 50 ± 10
Male, % 46 51 45
SBP, mmHg 118 ± 14 126 ± 13* 125 ± 17
DBP, mmHg 67 ± 10 74 ± 9** 74 ± 10**
Body mass index, kg/m2 25.6 ± 3.8 28.1 ± 5.8* 26.9 ± 6.1
Waist, cm 88.2 ± 11.7 96.0 ± 15.5* 92.3 ± 14.3
Diabetes, % 10 14 10
Total cholesterol, mmol/L 5.45 ± 0.86 5.30 ± 1.13 5.23 ± 1.20
LDL-C, mmol/L 3.45 ± 0.81 3.25 ± 1.12 3.19 ± 1.15
HDL-C, mmol/L 1.50 ± 0.33 1.44 ± 0.37 1.46 ± 0.45
Triglycerides, mmol/L 0.9 (0.7, 1.4) 1.30 (0.9, 1.6)** 1.0 (0.7, 1.7)
Never/ex/current smokers, % 77/19/4 40/34/26*** 28/52/20***
Anti-HT treatment, % 8 37*** 9##
LLT, % 4 11 5
FBS, mmol/L 4.8 (4.5, 5.2) 4.9 (4.5, 5.4) 4.6 (4.4, 5.2)
FRS 2.0 (0, 4.5) 4.0 (1.0, 12.0)** 2.0 (0, 8.0)
  1. Results were expressed as mean ± SD, or percentage or median (25, 75 percentile). *,**,*** vs. control p < 0.05, <0.01, <0.001, respectively, ##, vs. RA p < 0.01. Anti-HT treatment: anti-hypertensive treatment; ex-smoker: prior smokers who have not smoked in the last 12 months; DBP: diastolic blood pressure; FBS: fasting blood sugar; FRS: Framingham Risk Score; HDL-C: high-density lipoprotein cholesterol; IBD: inflammatory bowel disease; LDL-C: low-density lipoprotein cholesterol; LLT: lipid-lowering therapy; RA: rheumatoid arthritis; SBP: systolic blood pressure.